The pharmacokinetics of daunomycin in man

David S Alberts, Nicholas R. Bachur, Jordan L. Holtzman

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Through the use of fluorescence assay methods, the plasma levels, urinary excretion, and tissue levels o f daunomycin and its fluorescent metabolites were determined in patients treated with this drug for disseminated solid malignancies. The patients received daunomycin in a single rapid intravenous dose at 80 mg. per square meter and 120 mg. per square meter. Fluorescence studies showed the short plasma half-life to be 0.75 hours, the long plasma half-life to be 55 hours, the apparent volume of distribution to be about 1,000 L., and the relative volume of distribution to be 580 L. per square meter. Drug and fluorescent metabolites in urine averaged 13 to 14 per cent of the total dosage in 7 days. Tritiated daunomycin was used, but isotopic assay produced values different from those with fluorescence assay. These were interpreted to be the result o f tritium exchange or metabolism of the daunomycin. Daunomycin fluorescence was detected in autopsy specimens 16 and 19 hours after administration, with the highest levels in kidney, spleen, liver, and lung. The fluorescent species extracted from both plasma and urine consisted predominantly of daunomycin (D1) and daunomycin metabolite (D2), although small amounts o f the aglycones were detected. It is proposed that, because o f the long half-life o f daunomycin, the current treatment schedule be revised to a single intravenous dose.

Original languageEnglish (US)
Pages (from-to)96-104
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume12
Issue number1
StatePublished - Jan 1971
Externally publishedYes

Fingerprint

Daunorubicin
Pharmacokinetics
Fluorescence
Half-Life
Urine
Tritium
Pharmaceutical Preparations
Autopsy
Appointments and Schedules
Spleen
Kidney
Lung
Liver

ASJC Scopus subject areas

  • Pharmacology

Cite this

Alberts, D. S., Bachur, N. R., & Holtzman, J. L. (1971). The pharmacokinetics of daunomycin in man. Clinical Pharmacology and Therapeutics, 12(1), 96-104.

The pharmacokinetics of daunomycin in man. / Alberts, David S; Bachur, Nicholas R.; Holtzman, Jordan L.

In: Clinical Pharmacology and Therapeutics, Vol. 12, No. 1, 01.1971, p. 96-104.

Research output: Contribution to journalArticle

Alberts, DS, Bachur, NR & Holtzman, JL 1971, 'The pharmacokinetics of daunomycin in man', Clinical Pharmacology and Therapeutics, vol. 12, no. 1, pp. 96-104.
Alberts, David S ; Bachur, Nicholas R. ; Holtzman, Jordan L. / The pharmacokinetics of daunomycin in man. In: Clinical Pharmacology and Therapeutics. 1971 ; Vol. 12, No. 1. pp. 96-104.
@article{36d44237d82d4f2aaa105febe264d9ab,
title = "The pharmacokinetics of daunomycin in man",
abstract = "Through the use of fluorescence assay methods, the plasma levels, urinary excretion, and tissue levels o f daunomycin and its fluorescent metabolites were determined in patients treated with this drug for disseminated solid malignancies. The patients received daunomycin in a single rapid intravenous dose at 80 mg. per square meter and 120 mg. per square meter. Fluorescence studies showed the short plasma half-life to be 0.75 hours, the long plasma half-life to be 55 hours, the apparent volume of distribution to be about 1,000 L., and the relative volume of distribution to be 580 L. per square meter. Drug and fluorescent metabolites in urine averaged 13 to 14 per cent of the total dosage in 7 days. Tritiated daunomycin was used, but isotopic assay produced values different from those with fluorescence assay. These were interpreted to be the result o f tritium exchange or metabolism of the daunomycin. Daunomycin fluorescence was detected in autopsy specimens 16 and 19 hours after administration, with the highest levels in kidney, spleen, liver, and lung. The fluorescent species extracted from both plasma and urine consisted predominantly of daunomycin (D1) and daunomycin metabolite (D2), although small amounts o f the aglycones were detected. It is proposed that, because o f the long half-life o f daunomycin, the current treatment schedule be revised to a single intravenous dose.",
author = "Alberts, {David S} and Bachur, {Nicholas R.} and Holtzman, {Jordan L.}",
year = "1971",
month = "1",
language = "English (US)",
volume = "12",
pages = "96--104",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The pharmacokinetics of daunomycin in man

AU - Alberts, David S

AU - Bachur, Nicholas R.

AU - Holtzman, Jordan L.

PY - 1971/1

Y1 - 1971/1

N2 - Through the use of fluorescence assay methods, the plasma levels, urinary excretion, and tissue levels o f daunomycin and its fluorescent metabolites were determined in patients treated with this drug for disseminated solid malignancies. The patients received daunomycin in a single rapid intravenous dose at 80 mg. per square meter and 120 mg. per square meter. Fluorescence studies showed the short plasma half-life to be 0.75 hours, the long plasma half-life to be 55 hours, the apparent volume of distribution to be about 1,000 L., and the relative volume of distribution to be 580 L. per square meter. Drug and fluorescent metabolites in urine averaged 13 to 14 per cent of the total dosage in 7 days. Tritiated daunomycin was used, but isotopic assay produced values different from those with fluorescence assay. These were interpreted to be the result o f tritium exchange or metabolism of the daunomycin. Daunomycin fluorescence was detected in autopsy specimens 16 and 19 hours after administration, with the highest levels in kidney, spleen, liver, and lung. The fluorescent species extracted from both plasma and urine consisted predominantly of daunomycin (D1) and daunomycin metabolite (D2), although small amounts o f the aglycones were detected. It is proposed that, because o f the long half-life o f daunomycin, the current treatment schedule be revised to a single intravenous dose.

AB - Through the use of fluorescence assay methods, the plasma levels, urinary excretion, and tissue levels o f daunomycin and its fluorescent metabolites were determined in patients treated with this drug for disseminated solid malignancies. The patients received daunomycin in a single rapid intravenous dose at 80 mg. per square meter and 120 mg. per square meter. Fluorescence studies showed the short plasma half-life to be 0.75 hours, the long plasma half-life to be 55 hours, the apparent volume of distribution to be about 1,000 L., and the relative volume of distribution to be 580 L. per square meter. Drug and fluorescent metabolites in urine averaged 13 to 14 per cent of the total dosage in 7 days. Tritiated daunomycin was used, but isotopic assay produced values different from those with fluorescence assay. These were interpreted to be the result o f tritium exchange or metabolism of the daunomycin. Daunomycin fluorescence was detected in autopsy specimens 16 and 19 hours after administration, with the highest levels in kidney, spleen, liver, and lung. The fluorescent species extracted from both plasma and urine consisted predominantly of daunomycin (D1) and daunomycin metabolite (D2), although small amounts o f the aglycones were detected. It is proposed that, because o f the long half-life o f daunomycin, the current treatment schedule be revised to a single intravenous dose.

UR - http://www.scopus.com/inward/record.url?scp=0014975590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014975590&partnerID=8YFLogxK

M3 - Article

C2 - 5541137

AN - SCOPUS:0014975590

VL - 12

SP - 96

EP - 104

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -